title: Matrix metalloproteinases: drug targets for myocardial infarction.
abstract: Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.
authors: San Antonio Cardiovascular Proteomics Center, The University of Texas Health Science Center, San Antonio, TX 78245, USA.
authors: Andriy
authors: A
authors: Yabluchanskiy
authors: Yaojun
authors: Y
authors: Li
authors: Robert J
authors: RJ
authors: Chilton
authors: Merry L
authors: ML
authors: Lindsey
mesh_terms: D000818:Animals; D002465:Cell Movement; D003094:Collagen / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007797:Laminin / Q000378:metabolism; D008264:Macrophages / Q000502:physiology; D061965:Matrix Metalloproteinase Inhibitors / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*; D058628:Myofibroblasts / Q000502:physiology; D020556:Neutrophil Infiltration; D011509:Proteoglycans / Q000378:metabolism; D020257:Ventricular Remodeling
chemical_list: D005353:Fibronectins; D007797:Laminin; D061965:Matrix Metalloproteinase Inhibitors; D011509:Proteoglycans; D003094:Collagen